On behalf of the Board, M&A Securities is pleased to announce that Bursa Securities had, vide its letter dated 28 October 2020 (received on 30 October 2020), approved the listing of and quotation for up to 31,800,000 new ordinary shares in BKCB to be issued pursuant to the Private Placement....
(i) the issuance of 28,700,000 new Shares at the issue price of RM0.52 each pursuant to the Previous Private Placement, which raised proceeds of RM14.92 million;
(a) The Company intends to utilise RM15.0 million of the gross proceeds to partially repay the outstanding borrowings of the BKCB Group. As at 30 September 2020, the total bank borrowings of the Group (excluding lease liabilities) stood at approximately RM155.8 million which comprise mainly bank overdrafts, bankers acceptances, bill payables, revolving credit, term loans and hire purchase.
The minister also said the government has increased its allocation from RM1 billion to RM3 billion for immunisation for 70% of the population. Khairy was responding to a question from former health minister Datuk Seri Dzulkefly Ahmad (PH-Kuala Selangor), who asked if the number of vaccines in the country is going to be increased and for details on Malaysia’s participation in COVAX.
GNBT - Generex Biotechnology Corporation Other OTC - Other OTC Delayed Price. Currency in USD 0.1950 -0.0050 (-2.50%) At close: 3:58PM EST 4 November 2020
On behalf of the Board, M&A Securities wishes to announce that the Company has fixed the issue price of the Placement Shares at RM0.565 each.
The aforementioned issue price of RM0.565 per Placement Share represents a discount of approximately RM0.0587 or 9.41% from the five (5)-day weighted average market price of BKCB from 27 October 2020 to 3 November 2020 of approximately RM0.6237 per Share.
According to the agreement, Bintai Healthcare was granted the exclusive rights to distribute, sell and commercialize the new crown vaccine in Malaysia, Brunei, Myanmar, Cambodia, East Timor, Indonesia, Laos, the Philippines, Singapore, Thailand and Vietnam.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
DreamHunter
10,922 posts
Posted by DreamHunter > 2020-11-03 12:55 | Report Abuse
Still cool